Get our Free Patent Expiration, Litigation, and Drug Price Updates

Serving hundreds of leading biopharmaceutical companies globally:

Colorcon
UBS
AstraZeneca
McKinsey
Merck
Johnson and Johnson

Generated: May 26, 2019

DrugPatentWatch Database Preview

Details for Patent: 6,537,983

« Back to Dashboard

Summary for Patent: 6,537,983
Title: Anti-inflammatory androstane derivatives
Abstract:According to one aspect of the invention, there is provided a pharmaceutical formulation for administration by inhalation comprising a compound of formula (I), ##STR1## wherein R.sub.1 represents C.sub.1-6 alkyl or C.sub.1-6 haloalkyl; R.sub.2 represents --C(.dbd.O)-aryl or --C(.dbd.O)-heteroaryl; R.sub.3 represents hydrogen, methyl (which may be in either the .alpha. or .beta. configuration) or methylene; R.sub.4 and R.sub.5 are the same or different and each represents hydrogen or halogen; and ----- represents a single or a double bond; and salts and solvates thereof together with a long-acting .beta..sub.2 -adrenoreceptor agonist which formulation has a therapeutically useful effect in the treatment of inflammatory disorders of the respiratory tract over a period of 24 hours or more.
Inventor(s): Biggadike; Keith (Stevenage, GB), Jones; Paul Spencer (Stevenage, GB), Payne; Jeremy John (Stevenage, GB)
Assignee: SmithKline Beecham Corporation (Philadelphia, PA)
Application Number:10/066,961
Prior Art and Litigation SupportOrder Prior Art and Litigation support for Patent 6,537,983
Patent Claim Types:
see list of patent claims
Formulation; Compound; Use; Composition; Delivery;

Drugs Protected by US Patent 6,537,983

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Glaxo Grp Ltd BREO ELLIPTA fluticasone furoate; vilanterol trifenatate POWDER;INHALATION 204275-001 May 10, 2013 RX Yes Yes ➤ Sign Up ➤ Sign Up Y INDICATED FOR THE ONCE-DAILY INHALED TREATMENT FOR ASTHMA IN ADULTS AGED 18 YEARS AND OLDER ➤ Sign Up
Glaxo Grp Ltd BREO ELLIPTA fluticasone furoate; vilanterol trifenatate POWDER;INHALATION 204275-001 May 10, 2013 RX Yes Yes ➤ Sign Up ➤ Sign Up Y INDICATED FOR LONG-TERM, ONCE-DAILY MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PTS WITH COPD, INCLUDING CHRONIC BRONCHITIS AND/OR EMPHYSEMA, ALSO TO REDUCE EXACERBATIONS OF COPD IN PTS WITH A HISTORY OF EXACERBATIONS ➤ Sign Up
Glaxo Grp Ltd BREO ELLIPTA fluticasone furoate; vilanterol trifenatate POWDER;INHALATION 204275-002 Apr 30, 2015 RX Yes Yes ➤ Sign Up ➤ Sign Up Y INDICATED FOR THE ONCE-DAILY INHALED TREATMENT FOR ASTHMA IN ADULTS AGED 18 YEARS AND OLDER ➤ Sign Up
Glaxosmithkline TRELEGY ELLIPTA fluticasone furoate; umeclidinium bromide; vilanterol trifenatate POWDER;INHALATION 209482-001 Sep 18, 2017 RX Yes Yes ➤ Sign Up ➤ Sign Up Y THE TREATMENT OF AN INFLAMMATORY DISORDER OF THE RESPIRATORY TRACT BY ONCE-PER-DAY ADMINISTRATION OF A PHARMACEUTICAL FORMULATION COMPRISING FLUTICASONE FUROATE AND A LONG-ACTING BETA2 ADRENORECEPTOR AGONIST ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate

Subscribe to access the full database, or try a Free Trial

Foreign Priority and PCT Information for Patent: 6,537,983

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom0108800Apr 07, 2001

International Family Members for US Patent 6,537,983

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
African Regional IP Organization (ARIPO) 1422 ➤ Sign Up
Argentina 032361 ➤ Sign Up
Argentina 032471 ➤ Sign Up
Argentina 038348 ➤ Sign Up
Argentina 038686 ➤ Sign Up
Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Queensland Health
Johnson and Johnson
McKesson
Merck
Cantor Fitzgerald
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.